Arturo LoAIza-Bonilla, Systemwide Chief of Hematology and Oncology at St. Luke’s University Health Network, and Co-Founder and Chief Medical AI Officer (CMAIO) of Massive Bio, shared a post on LinkedIn:
“New in npj Precision Oncology (Nature Portfolio)!
A landmark review introduces a unified framework for oncology clinical trial pre-screening and screening—directly addressing one of cancer research’s biggest bottlenecks: efficient, equitable trial enrollment.
Clinical trial participation is still constrained by complex eligibility criteria, fragmented clinical data, and biomarker stratification—slowing recruitment and limiting access to cutting-edge therapies.
This paper synthesizes the full landscape, from manual workflows and health-system digital tools to AI-enabled screening, and shows how hybrid models that pair automation with clinician oversight can meaningfully improve the speed, accuracy, and fairness of trial matching across diverse populations.
Why this matters
- Makes trial matching smarter and more scalable
- Broadens access to investigational oncology therapies
- Explores how LLMs and modern digital frameworks can overcome key recruitment barriers
A must-read for clinicians, trial teams, AI innovators, and patient advocates advancing precision oncology in the real world.”
Title: A unified framework for pre-screening and screening tools in oncology clinical trials
Authors: Denis Horgan, Joe Paulson, Arturo Loaiza-Bonilla, Christer Svedman, Umberto Malapelle, Frédérique Penault Lorca, Hadi Mohamad Abu Rahsheed, Paul Hofman, Stan Kachnowsk, Daniel Schneider, Vivek Subbiah
Read the Full Article.
More posts featuring Arturo LoAIza-Bonilla.